The expression of p53 and bcl-2 in superficial bladder transitional cell carcinoma and its role in the outcome of postoperative intravesical chemotherapy

Anticancer Research

Volumn 18, Issue 6 B, 1998, Pages 4717-4721

  Tzai, Tzong Shin ^a   Chow, Nan Haw ^a   Lin, Johnny Shinn Nan ^a   Yang, Wen Hong ^a   Tong, Yat Ching ^a  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

Author keywords

Bcl 2; Bladder cancer; Chemotherapy; p53

Indexed keywords

EPIRUBICIN; PROTEIN BCL 2; PROTEIN P53; THIOTEPA;

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER STAGING; CANCER SURGERY; FEMALE; HUMAN; HUMAN TISSUE; INTRAVESICAL DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MULTIPLE CANCER; POSTOPERATIVE CARE; PREDICTION; PRIORITY JOURNAL; TRANSITIONAL CELL CARCINOMA; TRANSURETHRAL RESECTION; TREATMENT OUTCOME; TUMOR RECURRENCE;

ADMINISTRATION, INTRAVESICAL; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, TRANSITIONAL CELL; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; EPIRUBICIN; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROTO-ONCOGENE PROTEINS C-BCL-2; THIOTEPA; TUMOR SUPPRESSOR PROTEIN P53; URINARY BLADDER NEOPLASMS;

EID: 0032440016     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Soloway MS: Diagnosis and management of superficial bladder cancer. Semin Surg Oncol 5: 247-254, 1989.
2. Lane DP: Cancer. P53, guardian of the genome. Nature 358: 15-16, 1992.
3. Mercer WE, Avignolo C, Baserga R: Role of the p53 protein in cell proliferation as studied by microinjection of monoclonal antibodies. Mol Cell Biol 4: 276-281, 1984.
4. Ruley HE: p53 and response to chemotherapy and radiotherapy. In: Important Advances in Oncology. Edited by Devita VT Jr, Hellman S, Rosenberg SA. Philadelphia, Lippincott-Raven, 1996, pp37-56.
5. Lohmann D, Ruhri C, Schmitt M, Graeff H, Holler H: Accumulation of p53 protein as an indicator for p53 gene mutation in breast cancer. Occurrence of false-positives and false-negatives. Diagn Mol Pathol 2: 36-41, 1993.
6. Tsujimoto Y, Finger LR, Yunis J, Nowell PC, Croce CM: Cloning of the chromosome breakpoint of neoplastic B cells with t (14:18) chromosome translocation. Science 226: 1097-1099, 1984.
7. Hockenbery D, Nunez G, Milliman C, Schreiber RD, Korsmeyer SJ: Bcl-2 is an inner mitochodrial membrane protein that blocks programmed cell death. Nature 348: 334-336, 1990.
8. Zhan Q, Fan S, Bae I, Guillouf C, Liebermann DA, OëConnor PM, Fornace A JJr: Induction of bax by genotoxic stress in human cells correlates with normal p53 status and apoptosis. Oncogene 9: 3743-3751, 1994.
9. Thomas A, El Rouby S, Reed JC, Krajewski S, Silber R, Potmesil M, Newcomb EW: Drug-induced apoptosis in B-cell chronic lymphocytic leukemia: relationship between p53 gene mutation and bcl-2/bax proteins in drug resistance. Oncogene 12: 1055-1062, 1996.
10. Perego P, Giarola M, Righetti SC, Supino R, Caserini C, Delia D, Pierotti MA, Miyashita T, Red JC, Zunino F: Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems. Cancer Res 56: 556-562, 1996.
11. Lamm DL: Long-term results of intravesical therapy for superficial bladder cancer. Urol Clin North Am 19: 573-580, 1992.
12. Torti FM, Lum BL, Aston D, Mackenie N, Faysel M, Shortliffe LD, Freiha F: Superficial bladder cancer: the primacy of grade in the development of invasive disease. J Clin Oncol 5: 125-130, 1987.
13. Kaufmann SH: Induction of endonucleolytic DNA cleavage in human acute myelogenous leukemia cells by etoposide, camptothecin, and other cytotoxic anticancer drugs: a cautionary note. Cancer Res 49: 5870-5878, 1989.
14. Wright C, Mellon K, Johnston P, Lane DP, Harris AL, Horne CH, Neal DE: Expression of mutant p53 c-erb B2 and the epidermal growth factor in transitional cell carcinoma of the human urinary bladder. Br J Cancer 63: 967-978, 1991.
15. Dalbagni G, Presti JC, Reuter VE, Fair WR, Cordon-Card C: p53 and chromosome 17 abnormalities in bladder cancer. Proc Annu Meet Am Assoc Cancer Res 32: A2229, 1992.
16. Sarkis AS, Dalbagni G, Cordon-Cardo C, Zhang ZF, Sheinfeld J, Fair WR, Herr HW, Reuter VE: Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: A marker for disease progression. J Natl Cancer Inst 85: 53-59, 1993.
17. Esrig D, Elmajian D, Groshen S, Freeman JA, Stein JP, Chen SC, Nichols PW, Skinner DG, Jones PA, Cote RJ: Accumulation of nuclear p53 and tumor progression in bladder cancer. N Engl J Med 331: 1259-1264, 1994.
18. Zhong LT, Sarafian T, Kane DJ, Charles AC, Mah SP, Edwards RH, Bredesen DE: Bcl-2 inhibits death of central neural cells induced by multiple agents. Proc Natl Acad Sci USA 90: 4533-4537, 1993.
19. Ryan JJ, Prochownik E, Gottlieb CA, Apel IJ, Merino R, Nunez G, Clearke MF: c-myc and bcl-2 modulate p53 function by altering p53 subcellular trafficking during the cell cycle. Proc Natl Acad Sci USA 91: 5878-5882, 1994.
20. Shiina H, Igawa M, Urakami S, Honda S, Shirakawa H, Ishibe T: Immunohistochemical analysis of bcl-2 expression in transitional cell carcinoma of the bladder. J Clin Patho 49: 395-399, 1996.